(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 December 2020 (10.12.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/247643 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *A61K 31/497* (2006.01)
C07D 491/107 (2006.01)

(21) International Application Number:
PCT/US2020/036137

(22) International Filing Date:
04 June 2020 (04.06.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/858,837 07 June 2019 (07.06.2019) US

(71) Applicant: **REVOLUTION MEDICINES, INC.** [US/US]; 700 Saginaw Drive, Redwood City, California 94063 (US).

(72) Inventors: **LI, Shaoling**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US). **BALLMER, Steven G.**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US).

(74) Agent: **TONG, Connie C.** et al.; 1299 Pennsylvania Avenue, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2020/247643 A1

(54) Title: SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR

(57) Abstract: The present disclosure relates to crystalline solid forms of {6-[(2-amino-3-chloropyridin-4- yl)sulfanyl]-3-[(3,*S*,4*S*)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]- 5-methylpyrazin-2-yl}methanol, or a pharmaceutically acceptable salt thereof, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.